What are the main reasons Eli Lilly is presenting non-GAAP financial results?

Eli Lilly is presenting non-GAAP financial results to offer investors a clearer view of its ongoing operations. These adjusted measures exclude items that are typically highly variable and difficult to predict, such as special charges and restructuring costs, which can mask underlying operational trends. This allows for more meaningful period-over-period comparisons.

What specific items were excluded from the Q1 2012 and Q1 2011 results?

In Q1 2012, a special charge of $23.8 million related to the withdrawal of Xigris was excluded. In Q1 2011, the adjustments included in-process research and development charges from a diabetes collaboration with Boehringer Ingelheim, and restructuring charges from severance costs due to strategic workforce reductions.

How should investors interpret these non-GAAP financial measures?

Investors should consider these non-GAAP measures in addition to, not as a substitute for or superior to, the financial performance measures prepared in accordance with GAAP. The company believes these non-GAAP measures help evaluate ongoing operations and identify operating trends that might otherwise be obscured by excluded items.

Does this filing provide any forward-looking guidance?

Yes, the press release attached to this 8-K provides financial expectations for 2012, including earnings per share growth on a non-GAAP basis. However, the company notes that prospective earnings guidance is subject to adjustment for certain future matters, similar to those identified in the filing.

LLY 8-K: Earnings & Results

Summary

Eli Lilly and Company (LLY) filed an 8-K on April 25, 2012, to report its first-quarter 2012 financial results. The filing highlights the company's use of non-GAAP financial measures to provide a clearer view of ongoing operations, excluding one-time charges and special items. Investors are encouraged to consider these non-GAAP measures alongside GAAP results for a comprehensive understanding. The company adjusted its reported results to exclude a special charge of $23.8 million in Q1 2012 related to the withdrawal of Xigris. In Q1 2011, adjustments were made for in-process research and development charges linked to a diabetes collaboration with Boehringer Ingelheim, and restructuring charges from strategic workforce reductions. These adjustments aim to offer more meaningful period-over-period comparisons and insights into operating trends.

Key Highlights

1Announcement of Q1 2012 financial results via press release and teleconference.
2Company utilizes non-GAAP financial measures (net income, EPS) for enhanced operational insight.
3Q1 2012 results adjusted for a $23.8 million special charge related to Xigris withdrawal.
4Q1 2011 results adjusted for in-process R&D charges (diabetes collaboration) and restructuring costs.
5Non-GAAP measures are presented to help investors evaluate ongoing operations and identify trends.
6Financial expectations for 2012, including non-GAAP EPS growth, were provided.
7Filing includes a press release dated April 25, 2012, as Exhibit 99.

ELI LILLY & Co 8-K Report, Financial Results (Apr 25, 2012)

Summary

Key Highlights

Frequently Asked Questions